Heron Therapeutics (HRTX) Gross Margin (2016 - 2025)
Historic Gross Margin for Heron Therapeutics (HRTX) over the last 10 years, with Q3 2025 value amounting to 68.82%.
- Heron Therapeutics' Gross Margin fell 23500.0% to 68.82% in Q3 2025 from the same period last year, while for Sep 2025 it was 73.92%, marking a year-over-year increase of 17300.0%. This contributed to the annual value of 73.21% for FY2024, which is 244600.0% up from last year.
- Latest data reveals that Heron Therapeutics reported Gross Margin of 68.82% as of Q3 2025, which was down 23500.0% from 73.5% recorded in Q2 2025.
- Heron Therapeutics' Gross Margin's 5-year high stood at 78.26% during Q1 2025, with a 5-year trough of 18.55% in Q4 2021.
- In the last 5 years, Heron Therapeutics' Gross Margin had a median value of 44.58% in 2022 and averaged 43.33%.
- In the last 5 years, Heron Therapeutics' Gross Margin crashed by -729700bps in 2021 and then soared by 765000bps in 2022.
- Heron Therapeutics' Gross Margin (Quarter) stood at 18.55% in 2021, then skyrocketed by 412bps to 57.95% in 2022, then increased by 23bps to 71.12% in 2023, then increased by 5bps to 74.92% in 2024, then fell by -8bps to 68.82% in 2025.
- Its last three reported values are 68.82% in Q3 2025, 73.5% for Q2 2025, and 78.26% during Q1 2025.